AB
CRSP icon

Amalgamated Bank’s CRISPR Therapeutics CRSP Stock Holding History

Amalgamated Bank’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,739
Closed -$144K – 1907
2025
Q4 		$144K Buy
2,739
+57
+2% +$3.41K ﹤0.01% 1637
2025
Q3 		$174K Sell
2,682
-145
-5% -$8.32K ﹤0.01% 1603
2025
Q2 		$138K Buy
+2,827
New +$109K ﹤0.01% 1643

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Amalgamated Bank's CRSP Position: Q1 2026 in Review

Amalgamated Bank sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 2,739 shares — an estimated $144K sold.

Amalgamated Bank first reported a position in CRSP in Q2 2025 and held it in 3 quarters. The position peaked at $174K in Q3 2025. 492 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Amalgamated Bank reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 2,739 CRISPR Therapeutics shares in Q1 2026, an estimated $144K.
  • Amalgamated Bank first reported a position in CRISPR Therapeutics in Q2 2025 and held it in 3 quarters.
  • Amalgamated Bank's CRISPR Therapeutics position peaked at $174K in Q3 2025.
  • 492 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.